NASDAQ:CCCC
C4 Therapeutics, Inc.
C4 Therapeutics, Inc.'s revenue grew 1.0% in fiscal 2025 to $35.9M while operating margin rose to −320.5%. Free cash flow was −$99.3M, −276.2% of revenue, and the diluted share count rose 19.5%.Summary generated from C4 Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$35.9M
Revenue growth+1.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−320.5%
Net margin−292.1%
ROICn/a
Return on equity−44.4%
Debt / equityn/a
Free cash flow−$99.3M
FCF margin−276.2%
Share count change+19.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 46 | 31 | 21 | 36 | 36 |
| Operating income | −82 | −130 | −139 | −120 | −115 |
| Net income | −84 | −128 | −132 | −105 | −105 |
| Free cash flow | −88 | −111 | −109 | −65 | −99 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Oct 2, 2026 - 8-KRegulation FD disclosure
Sep 25, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 8-KResults of a shareholder vote
Jun 24, 2026 - 8-KRegulation FD disclosure
Jun 11, 2026 - 8-KDirector or officer change
May 15, 2026